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Abstract
Background: Insulin degludec/insulin aspart (IDegAsp) is a soluble coformulation
of the basal analog insulin degludec and the rapid-acting prandial insulin aspart
in a single injection. The present combined analysis of two Phase 3a trials com-
pared the incidence of hypoglycemia in participants treated twice daily with
IDegAsp or biphasic insulin aspart 30 (BIAsp 30).
Methods: Hypoglycemia data were analyzed from two similarly designed
randomized controlled open-label treat-to-target Phase 3a clinical trials of
adults with type 2 diabetes (T2D). Participants were treated twice daily with
IDegAsp or BIAsp 30, with breakfast and their main evening meal.
Results: Over 26 weeks, the rates of overall conﬁrmed, nocturnal conﬁrmed
and severe hypoglycemic events were 19%, 57%, and 39% lower, respectively,
with IDegAsp (n = 504) than BIAsp 30 (n = 364); estimated rate ratios were
0.81 (95% conﬁdence interval [CI] 0.67, 0.98; P = 0.0341), 0.43 (95% CI 0.31,
0.59; P = 0.0001), and 0.61 (95% CI 0.26, 1.45; P = NS). The between-
treatment differences were more pronounced during the maintenance period
(≥16 weeks); compared with BIAsp 30, rates of overall conﬁrmed, nocturnal
conﬁrmed and severe hypoglycemic events with IDegAsp were 0.69 (95% CI
0.55, 0.87; 31%; P = 0.0015); 0.38 (95% CI 0.25, 0.58; 62%; P < 0.0001),
and 0.16 (95% CI 0.04, 0.59; 84%; P = 0.0061), respectively.
Conclusions: Compared with BIAsp 30 twice daily, IDegAsp twice daily pro-
vided similar improvements in glycemic control with a lower risk of hypoglyce-
mia, particularly nocturnal hypoglycemia, in subjects with T2D previously
treated with insulin.
Keywords: b.i.d. treatment, biphasic insulin aspart 30, hypoglycemia, insulin
degludec/insulin aspart, type 2 diabetes.
Signiﬁcant ﬁndings of the study: Compared with BIAsp 30 administered twice daily, IDegAsp twice daily was as-
sociated with greater reductions in fasting plasma glucose, lower total daily insulin dose, and signiﬁcantly less
weight gain, as well as reductions in overall conﬁrmed, nocturnal, and severe hypoglycemia, particularly during
the maintenance period (≥16 weeks to end of trial).
What this study adds: For people requiring insulin intensiﬁcation, the availability of the coformulation IDegAsp
offers a more ﬂexible therapeutic option for improved glycemic control with a lower risk of hypoglycemia.
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Introduction
Insulin is an effective treatment for improving glycemic
control in people with type 2 diabetes (T2D). As the dis-
ease progresses, many people require further intensiﬁca-
tion of their treatment1 by either the sequential
addition of bolus insulin to basal regimens, the transition
to injections of premixed insulin,2 or the addition of a
glucagon-like peptide-1 receptor agonist.2 Adding bolus
insulin as a separate injection offers more precise control
of meal-time blood glucose than premixed insulin, but
people may ﬁnd this regimen complex to administer
and titrate.3 In addition, concerns over weight gain and
practical issues, such as the fear of injections and the in-
creased risk of hypoglycemia as a result of insulin inten-
siﬁcation, are considerable treatment barriers.4
A prospective preplanned meta-analysis of data from
seven Phase 3 clinical trials (ﬁve in people with T2D and
two in people with type 1 diabetes [T1D])5 demonstrated
that the basal insulin with an ultra-long duration of ac-
tion (i.e. insulin degludec [IDeg]), signiﬁcantly reduced
the risk of overall and nocturnal conﬁrmed hypoglyce-
mia compared with insulin glargine (IGlar). Insulin-
naïve participants experienced signiﬁcantly lower rates
of overall (rate ratio [RR] 0.83; 95% conﬁdence interval
[CI] 0.70, 0.98) and nocturnal conﬁrmed (RR 0.64; 95%
CI 0.48, 0.86) hypoglycemia episodes with IDeg com-
pared with IGlar. Reductions were most pronounced
during the maintenance period (≥16 weeks), after stable
glycemic control and insulin dose had been attained.5
Insulin degludec/insulin aspart (IDegAsp; Ryzodeg;
Novo Nordisk A/S, Søborg, Denmark) is a soluble
coformulation of IDeg, providing an ultra-long duration
of action, and IAsp, a rapid-acting insulin, in a single in-
jection6 that can be administered once or twice daily
with the main meal(s).7
At steady state, pharmacodynamic data showed that
IDegAsp provides distinct basal and prandial glucose-
lowering effects, with a peak action due to IAsp and a
ﬂat, stable basal effect due to IDeg, which was sustained
for ≥24 h.8 In contrast, biphasic insulin aspart (BIAsp)
has a shorter duration of action, lasting up to 22 h after
once-daily dosing.8 With simulated twice-daily use of
IDegAsp, exposure to the IDeg component was esti-
mated to be similar over the ﬁrst and second 12-h pe-
riods,9 and the pattern of the prandial peaks was
maintained and clearly separated from the ﬂat basal
glucose-lowering effects in participants with T1D, indi-
cating that no stacking should be observed with
IDegAsp when dosed twice daily.10
The clinical trial program for IDegAsp included two
Phase 3a open-label trials of twice-daily dosing versus
BIAsp 30 in people with T2D previously treated with
insulin: BOOST®^ INTENSIFY PREMIX I (global pa-
tient population) and BOOST®^: INTENSIFY ALL
(Asian patient population).11,12 The trials followed simi-
lar designs and used the same dose-titration algorithms
to attain glycemic targets, an atypical advantage in
performing a combined analysis of two studies.
Previously, a prespeciﬁed meta-analysis of hypoglyce-
mia rates demonstrated that improvements in HbA1c^
can be achieved with fewer hypoglycemic episodes, par-
ticularly nocturnal episodes, with IDeg versus IGlar
across a broad spectrum of people with diabetes.5 To ex-
tend the ﬁndings of that meta-analysis, a combined anal-
ysis of the two Phase 3a IDegAsp clinical trials in people
with T2D was performed in the present analysis using
similar methodology in order to demonstrate the superi-
ority of IDegAsp over BIAsp 30 in terms of fewer hypo-
glycemic episodes in people with T2D. Herein we report
the ﬁndings of a combined analysis of these two trials.
Methods
Trial design and participants
The present combined analysis comprised pooled partic-
ipant data from two Phase 3a clinical trials of IDegAsp
twice daily versus BIAsp 30 twice daily in insulin users
with advanced T2D. Both were randomized (1 : 1 in the
BOOST®^: INTENSIFY PREMIX I trial and 2 : 1 in
the BOOST®^: INTENSIFY ALL trial) controlled
open-label multicenter trials with a treat-to-target design
of 26 weeks duration (Table 1).11,12 Key recruitment
criteria included no history of recurrent severe hypogly-
cemia (≤1 severe hypoglycemic event in the previous 12
months) and baseline HbA1c^ 53–86 mmol/mol
(7.0%–10.0%). All participants were previously treated
for ≥3 months with either premixed insulin (once or
twice daily) ± oral antidiabetic drugs (OADs; metfor-
min, dipeptidyl peptidase-4 inhibitors and pioglitazone)
in the BOOST®^: INTENSIFY PREMIX I trial or with
basal, premixed or self-mixed insulin ± metformin in
the BOOST®^: INTENSIFY ALL trial. In both trials,
insulin was given with breakfast and the main evening
meal, and the dose was titrated using the same algorithm
to attain prebreakfast/pre-evening meal self-monitored
plasma glucose targets of 4.0–5.0 mmol/L. The proto-
col, its amendments, consent forms, and subject infor-
mation sheet were reviewed and approved by health
authorities according to local regulations and by the lo-
cal independent ethics committees prior to trial initia-
tion. In both studies, all HbA1c^ measurements were
performed with the same methodology at Quintiles cen-
tral laboratories (Quintiles Transnational, Durham,
NC, USA). Blood samples for HbA1c^ assessment were
analyzed using a Bio-Rad (Hercules, CA, USA) HPLC
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method, which was NGSP certiﬁed. The HbA1c^ samples
were collected at Visits 1, 2, 14, 18, and 28. Blood samples
to assess fasting plasma glucose (FPG) were analyzed
using a Roche Pharmaceuticals (Basel, Switzerland)
enzymatic method at the clinics. The FPG samples were
collected at Visits 2, 14, 18, and 28. Subjects had to attend
these visits while fasting.
These studies have been registered with ClinicalTrials.
gov (Global: IDNCT01009580; Asia: IDNCT01059812).
Assessments and statistical analysis
The primary endpoint in the present analysis was the
incidence of overall conﬁrmed hypoglycemia (plasma
glucose <3.1 mmol/L [56 mg/dL]; see Table 2) over
the full trial duration, including the maintenance period
(≥16 weeks of treatment). During the maintenance pe-
riod, hypoglycemic episodes were analyzed using a
negative binomial regression model, with treatment,
trial, sex, region, antidiabetic medicine at screening
(basal, premix), and age as explanatory variables. Se-
vere hypoglycemia, nocturnal conﬁrmed hypoglycemia
(0001–0559 hours) and non-severe hypoglycemia were
evaluated separately as subsets of overall conﬁrmed hy-
poglycemia (Table 2). In addition, overall symptomatic
conﬁrmed and nocturnal conﬁrmed hypoglycemia were
evaluated over the full trial period (Table 2). Non-
severe daytime and non-severe nocturnal hypoglycemia
were evaluated as subsets of overall hypoglycemia
(minus severe hypoglycemia) and hypoglycemia rates
were compared between treatments during the full trial
period, the titration period, and the maintenance period
(see Table S1, available as Supplementary Material to
this paper). A linear regression model (analysis of co-
variance [ANCOVA]) was used to analyze HbA1c^,
FPG, insulin dose (log transformed) and body weight,
with treatment, trial, sex, region, antidiabetic medicine
at screening (basal, premix), age and appropriate base-
line measurements as explanatory variables. Treatment-
emergent hypoglycemic episodes were counted for each
subject in each of the trials and analyzed using a nega-
tive binomial regression model with a log-link function
adjusted for treatment, trial, sex, geographic region,
antidiabetic medicine at screening (basal, premix), and
age and exposure period as an offset. The negative bi-
nomial model was chosen because it allows for the
Table 2 Classiﬁcation of hypoglycemic episodes
Category of hypoglycemic episode Deﬁnition used in IDegAsp Phase 3a studies
Non-severe hypoglycemia Episodes of hypoglycemia (symptomatic or asymptomatic) with conﬁrmation of plasma
glucose <3.1 mmol/L (56 mg/dL) or corresponding to full blood glucose <2.8 mmol/L
(50 mg/dL) that are handled by the subject himself/herself
Conﬁrmed hypoglycemia Episodes of hypoglycemia (symptomatic or asymptomatic) with a documented plasma glucose
level of <3.1 mmol/L (56 mg/dL), including episode(s) of severe hypoglycemia (below)
Severe hypoglycemia Episodes during which the subject required assistance in administering carbohydrates, glucagon
or other required resuscitative treatment
Nocturnal conﬁrmed hypoglycemia Episodes of conﬁrmed hypoglycemia that occurred between 0001 and 0559 hours (inclusive)
Symptomatic conﬁrmed hypoglycemia An event during which typical symptoms of hypoglycemia are accompanied by a measured
plasma glucose concentration (≤56 mg/dL; ≤3.1 mmol/L)
Table 1 Summary of trial designs and inclusion criteria
Trial (no. in the FAS)
BOOST®: INTENSIFY PREMIX I
(Global patient population; n = 446)
BOOST®: INTENSIFY ALL
(Asian patient population; n = 422)
Participating countries Australia, Denmark, Finland, India, Malaysia, Poland,
Sweden, Taiwan, Thailand, Turkey
Hong Kong, Japan, Malaysia, South Korea, Taiwan
Previous treatment(s) Premixed insulin (once or twice daily) ± OADs
for ≥3 months
Basal, premixed or self-mixed insulin ± metformin
for ≥3 months
Trial treatment IDegAsp twice daily ± metformin ± DPP-4i ± pio vs
BIAsp30 ± metformin ± DPP-4i ± pio
IDegAsp twice daily ± metformin vs BIAsp
30 ± metformin
Trial design Open randomized treat-to-target Open randomized treat-to-target
Duration of trial (weeks) 26 26
Randomization ratio
(IDegAsp vs BIAsp30)
1 : 1 2 : 1
BIAsp 30, biphasic insulin aspart 30; DPP-4i; dipeptidyl peptidase-4 inhibitor; FAS, full analysis set; IDegAsp, insulin degludec/insulin aspart; pio,
pioglitazone; OADs, oral antidiabetic drugs.
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heterogeneity between subjects that may arise because
of within-subject correlation.
All randomized subjects in the two trials were included
on the intent-to-treat principle. Rates of hypoglycemia
were expressed as the cumulative number of episodes
per patient-year of exposure; treatment differences were
reported as estimated rate ratios (ERRs) of
IDegAsp/BIAsp 30 with 95% CIs. Endpoints for
HbA1c^, FPG, insulin dose (log transformed), body
weight, and health-related quality of life (HRQoL) were
analyzed using a linear regression ANCOVA model,
with treatment, trial, sex, region, antidiabetic medicine
at screening (basal, premix), age and appropriate base-
line measurements as explanatory variables (except for
HRQoL). Norm-based scoring has been applied in this
trial for the HRQoL data (SF-36).13^
Results
Characteristics of baseline populations
The combined analysis included 868 participants, 504
treated with IDegAsp twice daily and 364 treated with
BIAsp 30 twice daily. Baseline characteristics for partic-
ipants in each of the Phase 3a trials are given in Table 3.
There were some differences in ethnicity between the
trial populations by design that reﬂect the trial locations:
because one trial was performed in 10 countries across
three continents and the trial population was classiﬁed
as ‘global’, whereas the other trial was performed in
South-East Asian countries.
Glycemic control
Analyses of the secondary efﬁcacy endpoints (HbA1c^
and FPG) are shown in Figures 1, 2. The estimated mean
treatment difference (IDegAsp–BIAsp 30) in HbA1c^ at
the end of the trial period was 0.00% (95% CI 0.11,
0.10; P = NS), indicating no difference between
IDegAsp and BIAsp 30 in a treat-to-target setting. In
the individual trials, the end-of-trial HbA1c^ data for
the global and Asian population trials were 0.03 (95%
CI 0.18, 013; P < 0.001) and 0.05 (95% CI 0.10,
0.20; P < 0.001), respectively. However, a signiﬁcantly
greater reduction in FPG was observed with IDegAsp
compared with BIAsp 30. The estimated mean treatment
difference was 1.12 mmol/L (95% CI 1.38, 0.85
[20.18 mg/dL; 95% CI 24.87, 15.31]; P < 0.0001).
The end-of-trial FPG values for the global and the Asian
population trials were 1.14 (95% CI 1.53, 0.76; P <
0.001) and 1.06 mmol/L (95% CI 1.43, 0.70; P <
0.001), respectively.
Hypoglycemia
Over the full trial period, there was a 19% lower rate of
overall conﬁrmed hypoglycemia with IDegAsp com-
pared with BIAsp 30 (ERR 0.81; 95% CI 0.67, 0.98; P
= 0.03; Fig. 3a; Table 4). The rates of daytime non-
severe hypoglycemic events reported with IDegAsp were
11% lower than those reported with BIAsp 30 (Table
S1). There was also a 57% reduction in the rate of noc-
turnal conﬁrmed hypoglycemia with IDegAsp (ERR
0.43; 95% CI 0.31, 0.59; P < 0.0001; Fig. 3b) and a
39% lower rate of severe hypoglycemia (ERR 0.61;
95% CI 0.26, 1.45; P = 0.27) compared with BIAsp 30.
The between-treatment reductions in hypoglycemia
rates were more pronounced during the maintenance
phase of treatment (from Week 16 until the end of the
trial; Table 4). Compared with BIAsp 30, IDegAsp was
associated with a 31% lower risk of overall conﬁrmed hy-
poglycemia (ERR 0.69; 95% CI 0.55, 0.87; P = 0.0015),
a 62% lower risk of nocturnal conﬁrmed hypoglycemia
Table 3 Baseline characteristics of the type 2 diabetes populations in the Phase 3a studies included in the combined analysis
Characteristic
BOOST®: INTENSIFY PREMIX I
(Global patient population)
BOOST®: INTENSIFY ALL
(Asian patient population)
IDegAsp b.i.d. BIAsp 30 b.i.d. IDegAsp b.i.d. BIAsp 30 b.i.d.
Full analysis set (n) 224 222 280 142
Men (%) 57.6 53.6 53.9 55.6
Race: White/Black/Asian/Other (%) 54.0/0.4/45.1/0.4 50.9/0.0/49.1/0.9 0.0/0.0/99.7/0.4 0.0/0.0/100.0/0.0
Age (years) 58.8 ± 9.9 58.8 ± 9.8 59.1 ± 10.2 61.2 ± 9.5
Weight (kg) 81.5 ± 18.1 78.9 ± 17.6 66.1 ± 11.2 66.0 ± 11.2
Body mass index (kg/m2) 29.6 ± 4.6 29.0 ± 4.9 25.4 ± 3.4 25.4 ± 3.7
Duration of diabetes (years) 12.8 ± 6.8 13.1 ± 7.4 16.3 ± 7.9 16.3 ± 8.2
HbA1c (%) 8.3 ± 0.8 8.4 ± 0.9 8.4 ± 0.8 8.4 ± 0.9
Mean HbA1c (mmol/mol) 67 68 68 68
FPG (mmol/L) 8.9 ± 2.9 8.6 ± 2.6 7.9 ± 2.5 7.9 ± 2.5
Unless stated otherwise, data are the mean ± SD. BIAsp 30, biphasic insulin aspart 30; FPG, fasting plasma glucose; IDegAsp, insulin degludec/
insulin aspart.
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(ERR 0.38; 95% CI 0.25, 0.58; P < 0.0001), and an 84%
lower risk of severe hypoglycemia (ERR 0.16; 95% CI
0.04, 0.59; P = 0.0061).
The rates of overall symptomatic conﬁrmed hypogly-
cemia reported over the full trial period were 28%
lower with IDegAsp (ERR 0.72; 95% CI 0.58, 0.89; P
= 0.0025) than BIAsp 30, whereas in the maintenance
period they were 36% lower with IDegAsp (ERR
0.64; 95% CI 0.49, 0.83; P = 0.0009) than BIAsp 30
(Table 4). In addition, the rates of nocturnal symptom-
atic conﬁrmed hypoglycemia reported over the full trial
period were 63% lower with IDegAsp (ERR 0.37; 95%
CI 0.26, 0.52; P < 0.0001) than BIAsp 30, whereas in
the maintenance period they were 64% lower with
IDegAsp (ERR 0.36; 95% CI 0.22, 0.57; P < 0.0001)
than BIAsp 30 (Table 4).
Insulin dose
Mean total daily insulin dose at the end of the trial pe-
riod was 16% lower for IDegAsp than BIAsp 30 (0.9 vs
1.1 U/kg; estimated mean dose ratio 0.84 [95% CI
0.80, 0.89]; P < 0.0001). Post hoc analyses revealed that
the RRs for end-of-trial insulin dose (IDegAsp/BIAsp 30)
were 0.89 (P = 0.002) and 0.79 (P < 0.0001) for the
individual BOOST®^: INTENSIFY PREMIX I and
BOOST®^: INTENSIFY ALL trials, respectively.
Weight gain
The pooled analysis identiﬁed a signiﬁcant difference be-
tween IDegAsp and BIAsp 30 in weight gain (estimated
mean treatment difference [IDegAsp–BIAsp 30] –0.50
kg; 95% CI 0.88, 0.11; P < 0.05). In the individual
Figure 1 Reduction in HbA1c^ over time during twice-daily (b.i.d.) treatment with insulin degludec/insulin aspart (IDegAsp) and biphasic insulin
aspart 30 (BIAsp 30). Data are the mean ± SEM based on full analysis set and last observation carried forward-imputed data. The vertical line at
16 weeks indicates the beginning of the maintenance period. CI, conﬁdence interval; NS, not signiﬁcant; SEM, standard error of the mean^.
Figure 2 Reduction in fasting plasma glucose (FPG) over time during twice-daily (b.i.d.) treatment with insulin degludec/insulin aspart (IDegAsp)
and biphasic insulin aspart 30 (BIAsp 30). Data are the mean ± SEM based on full analysis set and last observation carried forward-imputed data.
The vertical line at 16 weeks indicates the beginning of the maintenance period. CI, conﬁdence interval; SEM, standard error of the mean^.
IDegAsp vs BIAsp 30 in diabetes J.S. Christiansen et al.
© 2016 The Authors. Journal of Diabetes published by John Wiley & Sons Australia, Ltd and Ruijin Hospital, Shanghai Jiaotong University School of Medicine.724
trials, there was a signiﬁcant difference reported for the
global population trial (treatment difference [IDegAsp–
BIAsp 30] –0.62 kg; 95% CI 1.15, 0.10; P < 0.05),
but no signiﬁcant difference was reported in the Asian
Figure 3 Cumulative rate of (a) nocturnal conﬁrmed hypoglycemia and (b) nocturnal conﬁrmed hypoglycemia in the full 26-week period of the
Phase 3a clinical trials of insulin degludec/insulin aspart (IDegAsp) twice daily (b.i.d.) compared with biphasic insulin aspart 30 (BIAsp 30) twice
daily. Data show mean values based on the safety analysis set. Estimated risk reduction and P-values are from a negative binomial model. The
vertical line at 16 weeks indicates the beginning of the maintenance period.
Table 4 Combined analysis of hypoglycemia risk in subjects with type 2 diabetes in Phase 3a clinical trials of insulin degludec/insulin aspart
ERR (95% CI) IDegAsp/BIAsp 30
Full trial period (26 weeks) Maintenance period (≥16 weeks to end of trial)
Conﬁrmed hypoglycemia 0.81 (0.67, 0.98; P = 0.03) 0.69 (0.55, 0.87; P = 0.0015)
Nocturnal conﬁrmed hypoglycemia 0.43 (0.31, 0.59; P < 0.0001) 0.38 (0.25, 0.58; P < 0.0001)
Severe hypoglycemia 0.61 (0.26, 1.45; P = NS) 0.16 (0.04, 0.59; P = 0.0061)A
Symptomatic conﬁrmed hypoglycemia 0.72 (0.58, 0.89; P = 0.0025) 0.64 (0.49, 0.83; P = 0.0009)
Nocturnal symptomatic conﬁrmed hypoglycemia 0.37 (0.26, 0.52; P < 0.0001) 0.36 (0.22, 0.57; P < 0.0001)
ABased on three events in the insulin degludec/insulin aspart (IDegAsp) arm and 14 events in the biphasic insulin aspart 30 (BIAsp 30 arm).
ERR, estimated rate ratio; CI, conﬁdence interval.
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population (treatment difference [IDegAsp–BIAsp 30] –
0.38 kg; 95% CI 0.96, 0.21).
Health-related quality of life outcome
Based on data from the SF-36 questionnaire, IDegAsp
was associated with an improvement in the domain
Role-Emotional (between-treatment difference 1.43;
95% CI 0.06, 2.8). No signiﬁcant between-treatment dif-
ferences were observed in any other domains.
Composite efﬁcacy endpoints
Although there was no signiﬁcant between-treatment dif-
ference in the proportion of participants achieving
HbA1c^ <7.0%, the estimated odds ratio (EOR) was
1.68 (95% CI 1.13, 2.49; P = 0.0103; Fig. 4). The EOR
for participants who achieved an FPG target <5
mmol/L was 2.81 (95% CI 2.05, 3.86; P < 0.0001) and
the EOR for those who achieved an FPG target <5
mmol/L without nocturnal conﬁrmed hypoglycemia
was 2.74 (95% CI 1.92, 3.92; Fig. 4).
Adverse events
Both IDegAsp twice daily and BIAsp 30 twice daily were
tolerated well. The overall incidence and rate of adverse
events (AEs) was similar in the two trials. The most fre-
quent AEs in both treatment groups (in both trials) were
nasopharyngitis and upper respiratory tract infection.
The incidence of major adverse cardiovascular events
was low in both trials: three (1.3%) and two (0.9%)
events in the IDegAsp and BIAsp 30 arms of the
BOOST®^: INTENSIFY PREMIX I trial, respectively,
and one (0.4%) and ﬁve (3.5%) events in the IDegAsp
and BIAsp 30 arms of the BOOST®^: INTENSIFY
ALL trial, respectively.
Discussion
The present combined analysis of two randomized con-
trolled open-label treat-to-target Phase 3a clinical trials
of adults with T2D demonstrates that treatment with
IDegAsp twice daily provides effective overall glycemic
control that is comparable to BIAsp 30, with superior re-
duction in FPG consistent with the individual trials.11,12
The rates of overall conﬁrmed, nocturnal conﬁrmed, and
severe hypoglycemic events were lower with IDegAsp,
particularly during the maintenance period (≥16 weeks
to end of trial).
These results resemble those from a meta-analysis of
the IDeg clinical development program comparing IDeg
once daily to IGlar once daily,5 which demonstrated that
IDeg achieved similar glycemic control to IGlar with sig-
niﬁcantly lower rates of overall conﬁrmed, nocturnal
conﬁrmed, and severe hypoglycemia that were more pro-
nounced during the maintenance period in subjects with
T2D. The lower rates of hypoglycemia, particularly noc-
turnal hypoglycemia, may be linked to the ultra-long
and stable pharmacokinetic proﬁle and lower day-to-
day variability in glucose-lowering action of IDeg.14^
When coformulated in IDegAsp, the basal glucose-
lowering effect of IDeg is preserved and, at steady state,
IDegAsp displays a distinct peak (due to IAsp) and a
separate, ﬂat, basal action (due to IDeg) that are
retained following each dose.9 In contrast, the pharma-
codynamic proﬁle of BIAsp 30 exhibits an initial peak,
with a shoulder effect observed due to the overlapping
effects of the two forms of IAsp (30% soluble IAsp and
70% protaminated IAsp), followed by a gradual decline,
Figure 4 Estimated odds ratio (EOR). Participants achieving HbA1c^<7.0% and<7.0%without hypoglycemia in the last 12 weeks of treatment
and fasting plasma glucose (FPG) targets of <5.0 mmol/L and <5.0 mmol/L without (w/o) nocturnal hypoglycemia. Error bars represent 95%
conﬁdence intervals (CI). *This includes subjects exposed for at least 12 weeks, who met their HbA1c^ target without conﬁrmed hypoglycemia
during the last 12 weeks of treatment or within 7 days from the last treatment.
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returning to baseline values 18–22 h after injection.9
When compared side-by-side, the pharmacodynamic
proﬁles of the two insulins may explain the superior re-
ductions in FPG observed with IDegAsp reported here.
These properties of IDegAsp may also be associated
with the higher proportion of people achieving HbA1c^
<7.0% without conﬁrmed hypoglycemia in the past 12
weeks, as well as the chances of achieving an FPG target
<5 mmol/L without conﬁrmed nocturnal hypoglycemia.
Subjects receiving IDegAsp had lower rates of
conﬁrmed and nocturnal conﬁrmed hypoglycemia, re-
ductions that were more pronounced during the mainte-
nance period (≥16 weeks to end of trial), and a lower rate
of severe hypoglycemia during the maintenance period.
The rates of symptomatic conﬁrmed and nocturnal
symptomatic conﬁrmed hypoglycemia across the full
trial period were also lower with IDegAsp than BIAsp 30
and were sustained during the maintenance period
(Table 4). More detailed data on hypoglycemia rates
can be found in Tables S1, S2.
The clinical implications of a lower incidence of hypo-
glycemia during the trial can be exempliﬁed using a
‘numbers-needed-to-treat’ analysis. Based on the ERR
for the maintenance period and the observed rates of hy-
poglycemia, this means that for every 10 people treated
for 1 year with IDegAsp instead of BIAsp 30, there
would be 47 fewer overall hypoglycemic events, 19 fewer
nocturnal hypoglycemic events, and three fewer severe
hypoglycemic events.
The lower rate of hypoglycemia with IDegAsp is clini-
cally important because concerns over potential hypogly-
cemic events are a well-established barrier to people with
diabetes and physicians intensifying insulin therapy.3,15^
Hypoglycemic events affect HRQoL and cognitive
function16^ and are linked to cardiac effects, including ar-
rhythmias, myocardial ischemia, and cardiac failure.16^,17^
Severe hypoglycemic events create a major economic
burden due to emergency treatment and healthcare
costs,18^,19^ but non-severe hypoglycemic events occur
more frequently than severe events and account for the
majority of total events, incurring substantial economic
costs for employers and people with diabetes.20^
In the present post hoc analysis, end-of-trial daily
insulin dose was lower with IDegAsp, a ﬁnding that
was consistent with the individual trials, in which
RRs for end-of-trial insulin dose were lower with
IDegAsp than BIAsp.11,12
The lower dose requirement of IDegAsp may impact
cost-effectiveness, particularly in the Asian population,
in which premixed insulin is used more commonly.21^
Some endocrinologists prefer not to use ﬁxed-dose insu-
lin preparations because of a perception that separating
the basal and bolus components allows insulin dosages
to be better tailored to the person’s individual needs.22^
This is true, but the clear separation of basal and bolus
components in IDegAsp, together with the ﬂexibility in
the timing of administration,7,23^ provides more possibil-
ities for individualizing treatment than traditional
premixed preparations.
No unexpected safety issues associated with IDegAsp
were revealed in the present combined analysis, and there
were no apparent differences between IDegAsp and
BIAsp 30 with regard to the incidence and type of AEs.
A few of the limitations of this combined analysis in-
clude that both studies were open label because of differ-
ences in appearance between formulations. In addition,
despite the similarity of design of the two trials, there were
important differences between the two populations: par-
ticipants from the Asian population trial had lower body
weight, but a longer duration of diabetes12 compared
with the global population trial, which may have affected
insulin dose requirements and the risk of hypoglycemia.
Subjects in the BOOST®^: INTENSIFY PREMIX I
trial11 may also have had higher OAD usage because of
differences in the inclusion criteria. In addition, there
were differences in the pretrial insulin treatments allowed
within the inclusion criteria; however, these differences
were balanced across the treatment arms, so their impact
on the combined analysis was minimal.
In conclusion, the ﬁndings of the present combined
analysis show that IDegAsp twice daily provides compa-
rable HbA1c^ reductions and signiﬁcantly lower rates of
hypoglycemia than BIAsp 30 twice daily. This head-to-
head comparison of twice-daily dosing provides an im-
portant comparison of IDegAsp with BIAsp 30, the
most commonly used premixed insulin. For individuals
requiring insulin intensiﬁcation, the availability of
IDegAsp with its ultra-long duration of action and
rapid-acting prandial component offers an important
new therapeutic option to improve glycemic control with
a markedly lower risk of hypoglycemia.
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Supporting information
Additional Supporting Information may be found in the
online version of this article:
Table S1. Combined analysis of hypoglycemia rate ratios.
Table S2. Combined analysis of symptomatic hypoglycemia
risk.
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